{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:02:30Z","timestamp":1790265750281,"version":"4.1.0"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Primary central nervous system lymphoma is an aggressive lymphoma for which high-dose chemotherapy followed by autologous stem cell transplantation is standard first-line treatment in eligible patients; however, the optimal induction regimen remains uncertain. We conducted a multicenter international retrospective study across 11 centers including 355 transplant-eligible patients treated with MATRix (n=164), R-MPV\/R-MT (n=121), or the reduced-intensity Alberta protocol (n=70). The overall response rate was 89.5%, with a complete response rate of 50.1%. Although complete response rates were higher with R-MPV\/R-MT, transplantation rates were similar across regimens (74.4%, 69.4%, and 78.6%, respectively; p=0.36). Two-year overall survival was 79.0%, 89.0%, and 82.1% (p=0.32), and 2-year progression-free survival was 63.7%, 72.6%, and 75.3% (p=0.26) for MATRix, R-MPV\/R-MT, and Alberta, respectively. Comparable outcomes were also observed among patients proceeding to transplantation (n=261). Toxicity however differed substantially between regimens: MATRix was associated with higher rates of dose reductions (p=0.006), ICU admissions (p&amp;lt;0.001), and treatment-related mortality (p=0.006). After adjustment for baseline imbalances using inverse probability of treatment weighting, survival outcomes remained comparable across treatment groups, whereas MATRix retained a less favorable toxicity profile. Less intensive induction regimens achieved transplantation and survival outcomes comparable to MATRix while demonstrating superior tolerability, supporting treatment strategies that optimize tolerability without compromising long-term outcomes.<\/jats:p>","DOI":"10.1182\/bloodadvances.2026021352","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:11:15Z","timestamp":1790262675000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Induction intensity in transplant-eligible primary CNS lymphoma: no survival benefit despite increased toxicity"],"prefix":"10.1182","author":[{"given":"Vanja","family":"Zeremski","sequence":"first","affiliation":[{"name":"Otto-von-Guericke-University, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Puckrin","sequence":"additional","affiliation":[{"name":"University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-4271","authenticated-orcid":false,"given":"Farah","family":"Yassine","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, Wisconsin, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Stewart","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute in Edmonton, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Wauwatosa, Wisconsin, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4303-1683","authenticated-orcid":false,"given":"Tobias Ronny","family":"Haage","sequence":"additional","affiliation":[{"name":"Otto-von-Guericke University Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4308-2423","authenticated-orcid":false,"given":"Louisa","family":"Adolph","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-University Hospital, Munich,, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0609-2644","authenticated-orcid":false,"given":"Sina Alexandra","family":"Beer","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3452-0660","authenticated-orcid":false,"given":"Fabian","family":"G\u00f6rke","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Lei\u00fczig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-3112","authenticated-orcid":false,"given":"Jens P.","family":"Panse","sequence":"additional","affiliation":[{"name":"University Hospital, RWTH Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-4987","authenticated-orcid":false,"given":"Jessica","family":"Schneider","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[{"name":"Jena University Hospital, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Leipzig A\u00f6R, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-7125","authenticated-orcid":false,"given":"Hanno M.","family":"Witte","sequence":"additional","affiliation":[{"name":"University Hospital Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-6660","authenticated-orcid":false,"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[{"name":"University of Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,24]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026021352\/2591314\/bloodadvances.2026021352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026021352\/2591314\/bloodadvances.2026021352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:11:16Z","timestamp":1790262676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2026021352\/571181\/Induction-intensity-in-transplant-eligible-primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021352","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"bloodadvances.2026021352"}}